decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
Appendix E - National Coverage Determinations Manual / TUMOR_ANTIGEN_BY_IMMUNOASSAY_CA_15
Subscribe or sign in to view the full article.
Article Overview
This premium article covers National Coverage Determinations Manual guidance on tumor antigen testing by immunoassay, with a focus on CA 15-3 and CA 27.29. It explains the coverage context, the intended monitoring use of these tumor markers in malignancy management, and the limitations of coverage for certain diagnostic scenarios. The article is relevant to coders, billers, and clinical documentation staff working with laboratory testing and oncology-related services.
Why This Topic Matters
Understanding this coverage guidance helps users determine whether the article applies to breast cancer tumor marker monitoring and related Medicare policy context. It supports accurate interpretation of when the policy is relevant for documentation and claims review.
What You Will Learn
- The Medicare coverage context for tumor antigen immunoassay testing
- Which tumor markers are addressed by the policy
- The general clinical setting in which the guidance applies
- The stated coverage limitations for these services
Who Should Read This
- Medical coders
- Billing staff
- Compliance teams
- Oncology practices
- Laboratory services staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com